KY1102

KY1102 is a preclinical-stage small molecule non-steroidal anti-inflammatory drug (NSAID) developed by KYDES Pharmaceuticals. It is designed as a topical formulation for the localized treatment of arthritis, joint pain, and inflammation. As an NSAID, KY1102 likely functions by inhibiting cyclooxygenase (COX) enzymes, which are critical for the biosynthesis of prostaglandins that mediate pain and inflammatory responses. The topical route of administration is intended to provide targeted relief at the site of pain while potentially reducing the systemic exposure and gastrointestinal side effects commonly associated with oral NSAIDs.